What is Zacks Research's Forecast for UTHR FY2024 Earnings?

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Research analysts at Zacks Research upped their FY2024 EPS estimates for shares of United Therapeutics in a note issued to investors on Tuesday, November 19th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings of $24.45 per share for the year, up from their previous forecast of $23.30. The consensus estimate for United Therapeutics' current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics' Q1 2025 earnings at $6.93 EPS, Q2 2025 earnings at $6.63 EPS and Q2 2026 earnings at $6.47 EPS.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.38 earnings per share.

Several other equities research analysts also recently issued reports on the stock. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. Argus boosted their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Jefferies Financial Group lifted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the company a "buy" rating in a report on Monday, September 23rd. HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $364.33 on Thursday. The company's 50 day moving average price is $363.86 and its 200 day moving average price is $330.33. United Therapeutics has a one year low of $208.62 and a one year high of $417.82. The firm has a market capitalization of $16.27 billion, a price-to-earnings ratio of 16.00, a PEG ratio of 1.05 and a beta of 0.56.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. increased its holdings in shares of United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock valued at $652,000 after purchasing an additional 33 shares during the period. Toronto Dominion Bank boosted its stake in shares of United Therapeutics by 0.8% during the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock valued at $1,441,000 after buying an additional 37 shares during the period. ClariVest Asset Management LLC grew its holdings in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its position in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock valued at $109,000 after purchasing an additional 42 shares during the last quarter. Finally, First Citizens Bank & Trust Co. increased its position in United Therapeutics by 1.8% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock worth $961,000 after purchasing an additional 48 shares during the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of United Therapeutics stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. This trade represents a 67.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 109,796 shares of company stock valued at $40,936,370 over the last three months. Company insiders own 11.90% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.